Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice;Wirksamkeit und sicherheit einer akuttherapie mit GPIIb/IIIa- rezeptorblockern bei ischämischem zerebralem insult in der klinisch-internistischen routine

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 12, 2004, Pages 607-610

  Haerten, K ^a,b   Krabbe, Chr ^a   Raiber, M ^a  

^a Marien Hospital   (Germany)

^b MARIEN HOSPITAL WESEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANKIN SCALE; RATING SCALE; RETROSPECTIVE STUDY; STROKE; SYMPTOMATOLOGY; THROMBOCYTE AGGREGATION INHIBITION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; BRAIN; BRAIN ISCHEMIA; CAROTID ARTERIES; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEPARIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; TICLOPIDINE; TOMOGRAPHY, X-RAY COMPUTED; TYROSINE; ULTRASONOGRAPHY, DOPPLER;

EID: 1642411466     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-820569     Document Type: Article

References (15)

1. Abumiya T, Fitridge R, Mazur C et al. Integrin alpha (IIb) beta (3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000; 31: 1402-1409
2. Caprie steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1339
3. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo - controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649
4. Chamorro A. Immediate anticoagulation in acute focal brain ischemia revisited: gathering the evidence. Stroke 2001; 32: 577-578
5. Chamorro A, Vila N, Saiz A et al. Early anticoagulation after large cerebral embolic infarction. Neurology 1995; 45: 861-865
6. Diener HC, Cuhna C, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
7. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 334: 1215-1220
8. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349: 1569-1581
9. Junghans U, Seitz RJ, Aulich A et al. Bleeding risk of tirofiban, a nonpeptide GPIIb/ IIIa platelet receptor antagonist in progressive stroke. Cerebrovasc Dis 2001; 12: 308-312
10. Junghans U, Siebler M. Cerebral microembolism is blocked by Tirofiban, a selective nonpeptide platelet Glycoprotein IIb/IIIa Receptor Antagonist. Circulation 2003; 107: 2717-21
11. Junghans U, Seitz RJ, Ritzl A et al. Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban. Neurology 2002; 58: 474-476
12. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke. JAMA 2000; 283: 1151-1158
13. Memon MA, Blankenship JC, Woods GC et al. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000; 109: 213-217
14. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic stroke. The New England Journal of Medicine 1995; Vol. 333, No. 24: 1581-1587
15. Scheller B, Hennen B, Böhm M et al. Bedeutung von GP IIb/IIIa - Rezeptor - Antagonisten in der invasiven Kardiologie. Dtsch Med Wochenschr 2003; 128: 281-287